Anosmia and / or Ageusia and Early Corticosteroid Use
Launched by CLINAMYGATE · Aug 26, 2020
Trial Information
Current as of May 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how quickly people recover from loss of smell (anosmia) or taste (ageusia) after having COVID-19 when they are treated with corticosteroids early on. Corticosteroids are a type of medication that can help reduce inflammation in the body. The study is currently recruiting participants who are 18 years or older and have mild to moderate COVID-19 symptoms.
To join the trial, you must not have diabetes or any other health issues that would prevent you from taking the medication being studied. If you participate, you can expect to receive treatment and be monitored for your recovery over time. This trial aims to help researchers understand if early use of corticosteroids can improve recovery from these specific symptoms of COVID-19.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Any case with COVID-19
- • Age more than or equal to 18 years
- • Mild to moderate severity
- Exclusion Criteria:
- • Diabetes
- • Any contra-indication for the interventional drug
- • Mentally disabled cases
About Clinamygate
Clinamygate is a leading clinical trial sponsor dedicated to advancing medical research and innovation through the development and management of comprehensive clinical studies. With a focus on enhancing patient outcomes and accelerating the drug development process, Clinamygate collaborates with a diverse range of stakeholders, including pharmaceutical companies, research institutions, and healthcare providers. Our commitment to ethical practices and regulatory compliance ensures the highest standards of safety and efficacy in all trials. By leveraging cutting-edge technologies and a robust network of clinical sites, Clinamygate aims to bring transformative therapies to market efficiently and effectively, ultimately improving global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maadi, Cairo, Egypt
Patients applied
Trial Officials
Emad R Issak, MD
Study Director
Assalam Clinics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials